Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.

IF 3 4区医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-03-01 Epub Date: 2023-08-02 DOI:10.2217/fon-2023-0372

Simone Critchlow, Ash Bullement, Simon Crabb, Robert Jones, Katerina Christoforou, Amerah Amin, Ying Xiao, Venediktos Kapetanakis, Ágnes Benedict, Jane Chang, Mairead Kearney, Anthony Eccleston

{"title":"Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.","authors":"Simone Critchlow, Ash Bullement, Simon Crabb, Robert Jones, Katerina Christoforou, Amerah Amin, Ying Xiao, Venediktos Kapetanakis, Ágnes Benedict, Jane Chang, Mairead Kearney, Anthony Eccleston","doi":"10.2217/fon-2023-0372","DOIUrl":null,"url":null,"abstract":"Aim: The cost-effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed. Materials & methods: A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost-effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY). Results: Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses. Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"459-470"},"PeriodicalIF":3.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2023-0372","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The cost-effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed. Materials & methods: A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost-effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY). Results: Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses. Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

苏格兰阿维列单抗一线维持治疗晚期尿路上皮癌的成本效益分析。

目的：评估苏格兰阿维列单抗一线维持治疗局部晚期或转移性尿路上皮癌的成本效益。材料与方法：结合 JAVELIN Bladder 100 试验数据、国家数据库和已发表文献中的成本以及临床专家对假设的验证，建立了一个分区生存模型，对阿维单抗加最佳支持治疗 (BSC) 与单用 BSC 进行比较。使用终生成本和质量调整生命年（QALY）估算了增量成本效益比（ICER）。结果显示阿维鲁单抗加 BSC 的增量成本为 9446 英镑，QALY 增益为 0.63，导致每 QALY 增益的基础案例（确定性）ICER 为 15046 英镑，并得到稳健的敏感性分析的支持。结论在苏格兰，阿维单抗一线维持治疗可能是一种具有成本效益的局部晚期或转移性尿路上皮癌治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.